Appointed
Dominic Rodrigues
President
PVCT ·
PROVECTUS BIOPHARMACEUTICALS, INC.
appointed Dominic Rodrigues as the Company’s President effective April 16, 2024.
Ready 8-Ks
35
Latest filing
June 30, 2026, 7:37 PM ET
Top materiality
0.80
Event mix
other_material ×18 · other ×10 · debt ×4
Sentiment
2 pos · 0 neg · 33 neu
Executive change
recent →
Recent 8-K filings for PVCT
Highest-materiality recent filing
Provectus Biopharmaceuticals Names Dominic Rodrigues Principal Executive Officer; Bruce Horowitz Resigns
- Bruce Horowitz resigned as COO and Director on March 25, 2024, and entered a termination agreement with a total payment of up to $750,000.
- The termination agreement includes an initial $250,000 payment and a second payment of $258,000 if paid before June 30, 2024, otherwise $500,000.
-
Provectus Biopharma approves up to $10M convertible loan financing for drug development
Board approved 2025 Term Sheet to arrange up to $10M unsecured convertible loan in tranches.
-
Provectus launches VisiRose subsidiary to develop RB PDAT for eye infections
VisiRose formed as Delaware subsidiary to commercialize rose bengal sodium for ophthalmology, targeting infectious keratitis.
-
Provectus converts $2.13M in director fees to Series D-1 Preferred shares
Converted $2,131,838.75 in accrued directors’ fees into 744,878 shares of Series D-1 Preferred at $2.862 per share.
-
Provectus announces up to $10M convertible loan financing at 8% interest
Board approved term sheet for up to $10M unsecured convertible loan (2024 Financing) from multiple investors.
-
Provectus licenses University of Miami's rose bengal PDAT for eye infections; will form spinout
Exclusive worldwide license for photodynamic antimicrobial therapy (PDAT) using rose bengal sodium to treat bacterial, fungal, and acanthamoeba keratitis.
-
Bruce Horowitz resigned as COO and Director on March 25, 2024, and entered a termination agreement with a total payment of up to $750,000.
-
Provectus Biopharma stockholders authorize reverse stock split and reduce authorized shares
Reverse stock split approved (321.7M for) at ratio of 1:10 to 1:50, Board to determine exact ratio.
-
Provectus Biopharmaceuticals approves up to $5M convertible note financing
Board approved term sheet for up to $5M in convertible notes; proceeds fund drug discovery and G&A.
-
Provectus Biopharma approves up to $5M convertible loan; CFO invests $200K
Board approved financing term sheet for up to $5,000,000 unsecured convertible loan.
Executive changes
Appointed
Ed Pershing
Chief Executive Officer
PVCT ·
PROVECTUS BIOPHARMACEUTICALS, INC.
appointed Ed Pershing as the Company’s Chief Executive Officer effective April 16, 2024.
Appointed
Dominic Rodrigues
Chief Operations Consultant
PVCT ·
PROVECTUS BIOPHARMACEUTICALS, INC.
the Board retained Dominic Rodrigues as the Company’s chief operations consultant.
Departed
Bruce Horowitz
Chief Operating Officer
PVCT ·
PROVECTUS BIOPHARMACEUTICALS, INC.
On March 25, 2024, Bruce Horowitz resigned from the Board of Directors (the “Board”) of Provectus Biopharmaceuticals, Inc. (the “Company”) and as the Company’s Chief Operating Officer.
Departed
Bruce Horowitz
Director
PVCT ·
PROVECTUS BIOPHARMACEUTICALS, INC.
On March 25, 2024, Bruce Horowitz resigned from the Board of Directors (the “Board”) of Provectus Biopharmaceuticals, Inc. (the “Company”) and as the Company’s Chief Operating Officer.
Materiality & sentiment trend
Max materiality 0.80 · Median 0.50 · Most common event other_material